Immunobiologicals in severe asthma: case report
Immunobiologicals in severe asthma: case report
DOI:
https://doi.org/10.53660/CLM-3669-2441APalavras-chave:
Asthma;, Asthma; Global Initiative for Asthma, Long-acting muscarinic antagonist, Long-acting β2-agonist, Inhaled corticosteroid, ImmunobiologicalsResumo
According to the Global Initiative for Asthma (GINA), asthma is a chronic-inflammatory respiratory disease, characterized by limitation of expiratory air flow, dyspnea, wheezing and tachypnea, especially at night or in contact with allergens, climate changes or presence of environmental pollution. Among its subtypes, severe asthma stands out, where the symptomatic condition persists despite optimized treatment at advanced levels. The present study is a case report associated with a literature review on the use of immunobiologicals in the clinical treatment of severe asthma. Female patient, 53 years old, history of late-onset asthma at age 25, with frequent exacerbations, using drug therapy based on inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) in a single inhaler associated with the use of oral corticosteroids. After confirming the diagnosis of severe non-allergic eosinophilic asthma of endotype T2, GINA 5, the patient started treatment with mepolizumab and months later she showed significant improvement with the use of the immunobiological 1x/month and use of ICS associated with LABA. 12/12h, without the need for oral corticosteroids and use of rescue medications less than 2x/week.
Downloads
Referências
AARON, Shawn D. et al. Overdiagnosis of asthma in obese and nonobese adults. Cmaj, v. 179, n. 11, p. 1121-1131, 2008a.
AARON, Shawn D. et al. Underdiagnosis and overdiagnosis of asthma. American journal of respiratory and critical care medicine, v. 198, n. 8, p. 1012-1020, 2018b.
ANAGNOSTOU, Katherine et al. Risk factors for childhood asthma deaths from the UK Eastern Region Confidential Enquiry 2001–2006. Primary Care Respiratory Journal, v. 21, n. 1, p. 71-77, 2012.
BLEECKER, Eugene R. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. The Lancet, v. 388, n. 10056, p. 2115-2127, 2016.
BOURDIN, Arnaud et al. Phenotyping of Severe Asthma in the Era of Broad-acting Anti-asthma Biologics. The Journal of Allergy and Clinical Immunology: In Practice, 2024.
BRITISH THORACIC ASSOCIATION et al. Death from asthma in two regions of England. Br Med J (Clin Res Ed), v. 285, n. 6350, p. 1251-1255, 1982.
CARVALHO-PINTO, Regina Maria de et al. Recomendações para o manejo da asma grave da Sociedade Brasileira de Pneumologia e Tisiologia-2021. Jornal Brasileiro de Pneumologia, v. 47, p. e20210273, 2021.
CHIPPS, Bradley E. et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. Journal of Allergy and Clinical Immunology, v. 139, n. 5, p. 1431-1444, 2017.
CHUNG, Kian Fan et al. Characteristics, phenotypes, mechanisms and management of severe asthma. Chinese Medical Journal, v. 135, n. 10, p. 1141-1155, 2022.
HUANG, Kewu et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. The Lancet, v. 394, n. 10196, p. 407-418, 2019.
LEVY, Mark. et al. Confidential Enquiry Report. Why Asthma Still Kills: the National Review of Asthma Deaths (NRAD). London, UK: Royal College of Physicians, 2014.
LEVY, Mark L. et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ primary care respiratory medicine, v. 33, n. 1, p. 1-13, 2023.
LEVY, Mark L. The national review of asthma deaths: what did we learn and what needs to change?. Breathe, v. 11, n. 1, p. 14-24, 2015.
OPPENHEIMER, John et al. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Annals of Allergy, Asthma & Immunology, v. 129, n. 2, p. 169-180, 2022.
ORTEGA, Hector G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England journal of medicine, v. 371, n. 13, p. 1198-1207, 2014.
